Maury Raycroft
Stock Analyst at Jefferies
(1.82)
# 3,329
Out of 5,090 analysts
55
Total ratings
35.71%
Success rate
-7.97%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Buy | $108 → $134 | $106.01 | +26.40% | 2 | Dec 2, 2025 | |
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $15.33 | +36.99% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.35 | +18.52% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $464.56 | +18.18% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.24 | +12.18% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $24.51 | -38.80% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.16 | +62.04% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $10.70 | +395.33% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $5.59 | +43.24% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.54 | +460.22% | 1 | Dec 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.04 | +243.98% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $3.23 | +85.76% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $9.88 | +92.31% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $3.85 | +289.61% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $44.90 | -13.13% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.56 | +980.69% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.80 | +1,181.34% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $3.42 | +5,601.75% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.86 | +40.04% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $42.61 | -85.92% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $64.67 | +15.97% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $9.59 | +14.65% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $21.97 | +22.91% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.93 | +159.07% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $8.73 | +312.37% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.93 | +1,672.15% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $58.85 | +192.27% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.71 | +1,635.09% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $9.77 | +330.11% | 3 | Nov 1, 2017 |
Celcuity
Dec 2, 2025
Maintains: Buy
Price Target: $108 → $134
Current: $106.01
Upside: +26.40%
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $15.33
Upside: +36.99%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.35
Upside: +18.52%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $464.56
Upside: +18.18%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.24
Upside: +12.18%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $24.51
Upside: -38.80%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.16
Upside: +62.04%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $10.70
Upside: +395.33%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $5.59
Upside: +43.24%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.54
Upside: +460.22%
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.04
Upside: +243.98%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $3.23
Upside: +85.76%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $9.88
Upside: +92.31%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.85
Upside: +289.61%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $44.90
Upside: -13.13%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.56
Upside: +980.69%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.80
Upside: +1,181.34%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $3.42
Upside: +5,601.75%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.86
Upside: +40.04%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $42.61
Upside: -85.92%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $64.67
Upside: +15.97%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $9.59
Upside: +14.65%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $21.97
Upside: +22.91%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.93
Upside: +159.07%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $8.73
Upside: +312.37%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.93
Upside: +1,672.15%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $58.85
Upside: +192.27%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.71
Upside: +1,635.09%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $9.77
Upside: +330.11%